Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-05
2006-09-05
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C514S314000
Reexamination Certificate
active
07101894
ABSTRACT:
Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula:wherein Ar is a substituted or unsubstituted 5–14 membered heteroaryl group having from 1 to 5 heteroatoms as ring members; R1is selected from the group consisting of substituted or unsubstituted aryl(C1–C4)alkyl, heteroaryl(C1–C4)alkyl, —C(O)R11, and —C(O)NR11R12, wherein each R11and R12independently is substituted or unsubstituted aryl, substituted or unsubstituted aryl(C1–C4)alkyl, substituted or unsubstituted (C4–C8)cycloalkyl(C1–C4)alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl(C1–C4)alkyl and substituted or unsubstituted hetero(C4–C8)cycloalkyl(C1–C4)alkyl; R2is H or (C1–C8)alkyl; and ZNis a substituted or unsubstituted hetero(C6–C10)bicycloalkyl group.
REFERENCES:
patent: 3432301 (1969-03-01), Rauhut et al.
patent: 4444778 (1984-04-01), Coughlin
patent: 5935995 (1999-08-01), Bosslet et al.
patent: 5948775 (1999-09-01), Koko et al.
patent: 6034102 (2000-03-01), Aiello
patent: 6150132 (2000-11-01), Wells et al.
patent: 6156752 (2000-12-01), Ikeda et al.
patent: 6420121 (2002-07-01), Nelson et al.
patent: 6596497 (2003-07-01), Jiang et al.
patent: 2002/0061599 (2002-05-01), Elling et al.
patent: 2002/0127544 (2002-09-01), Schall et al.
patent: 2002/0176870 (2002-11-01), Schall et al.
patent: 2002/0193374 (2002-12-01), Schall et al.
patent: 2003/0114423 (2003-06-01), McMaster et al.
patent: 2003/0175681 (2003-09-01), Schall et al.
patent: 0 795 334 (1997-09-01), None
patent: 6414808 (1965-07-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/11073 (1998-03-01), None
patent: WO 00/00491 (2000-01-01), None
patent: WO 00/11950 (2000-03-01), None
patent: WO 00/55377 (2000-09-01), None
patent: WO 02/17900 (2002-03-01), None
patent: WO 02/17969 (2002-03-01), None
patent: WO 02/18954 (2002-03-01), None
Sime et al, J.Chem Soc. Perkin Trans. 1, 1992 pp. 1653-1658.
Field's Virology, Field et al, Eds., Lippincott-Raven, Phila. PA, 1995, pp. 2496-2497 and 2506-2507.
Lacini et al70CA:97146, 1984.
55CA:132044, Hsu, Chiao-Mu, 1960.
Tan et al. “Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase,” Journal of Natural Products, 1991, vol. 54, No. 1, pp. 143-154.
Verma et al. “Cinchona alkaloids as inhibitors of potato virus X,” American College of physicians, Bulletin, 1970, vol. 5, No. 2-4, pp. 203-210, Abstract, CAPLUS AN 1971:548640.
Beisser et al., 2002, “Viral Chemokine Receptors and Chemokines in Human Cytomegalovirus Trafficking and Interaction with the Immune System,”Curr. Top. Microbiol. Immunol.269:203-234.
Debnath et al., 1999, “Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type I,”J. Med. Chem.42:3203-3209.
Horuk, R., 1994, “Molecular properties of the chemokine receptor family”,Trends Pharm. Sci.15:159-165.
Kledal et al., 1998, “Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28,”FEBS Letters441:209-214.
Michelson, S., 1999, “Cytomegalovirus (CMV) and sequestration of chemokines,”Eur. Cytokine Netw.10(2): 286-287.
Schall et al., 1994, “Chemokines, leukocyte trafficking, and inflammation,”Curr. Opin. Immunol.6:865-873.
Schall, T., 1991, “Biology of the Rantes/SIS Cytokine Family,”Cytokine3(3): 165-183.
Beers, Mark H. et al. “The Merck Manual of Diagnosis and Therapy” esp. pp. 1295-1296; Merck Research Laboratories, Whitehouse Station, NJ (1999).
Beisser, Patrick S. et al.: “The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection”;Journal of Virology; Mar. 1998; vol. 72, No. 3; pp. 2352-2363; American Society for Microbiology.
Beisser, Patrick S. et al.: “Deletion of the R78 G protein-coupled receptor gene from rat cytomegalovirus results in an attenuated, syncytium-inducing mutant strain”;Journal of Virology; Sep. 1999; vol. 73, No. 9; pp. 7218-7230; American Society for Microbiology.
Billstrom, Marcella A. et al.: “Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection”;Journal of Virology; Jul. 1998; vol. 72, No. 7; pp. 5535-5544.
Bodaghi, Bahram, et al.: “Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells”;J. Exp. Med.; Sep. 7, 1998; vol. 188, No. 5; pp. 855-866.
Casarosa, Paola et al.: “Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor”;Journal of Biological Chemistry; Feb. 14, 2003; vol. 278; No. 7; pp. 5172-5178.
Davis-Poytner, Nicholas J. and Helen E. Farrell: “Masters of deception: A review of herpesvirus immune evasion strategies”;Immunology and Cell Biology; 1996; No. 74; pp. 513-522.
Davis-Poytner Nicholas J. et al.: “Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus”;Journal of Virology, Feb. 1997; vol. 71, No. 2; pp. 1521-1529; American Society for Microbiology.
Farrell, H.E. et al.: “Inhibition of natural killer cells by a cytomegalovirus MHC class I homogluein vivo”; Nature; Apr. 3, 1997; vol. 386; pp. 510-514.
Fleming, Peter et al.: “The murine cytomegalovirus chemokine homolog, m131/129, is a determinant of viral pathogenicity”;Journal of Virology; Aug. 1999; vol. 73, No. 8; pp. 6800-6809; American Society for Microbiology.
Gao J.L. and P.M. Murphy: “Human citomegalovirus open reading frame US28 encodes a functional beta chemokine receptor”;J. Biol. Chem; Nov. 18, 1994; vol. 269, No. 46; pp. 28539-28542.
Goodman, L.S. et al.: “The Pharmacological Basis of Therapeutics” 9th ed.; esp. pp. 51-58, (1995).
Grundy, Jane E., et al.: Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transeridothelial migration:;The Journal of Infectious Diseases; 1998; vol. 177; pp. 1465-1474.
Kitaguchi, Tetsuya et al.: “Characterization of liposomes carrying von Willebrand factor-binding domain of platelet glycoprotein lbα: A potential substitute for platelet transfusion”;Biological and Biochemical Research Communications; 1999; vol. 261; pp. 784-789; Academic Press, Inc.
Kledal, Thomas N. et al.: “A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus”;Science; Sep. 12, 1997; vol. 277; pp. 1656-1659.
Mahalingam, Surendran and Gunasegaran Karupiah: “Chemokines and chemokine receptors in infectious diseases”;Immunology and Cell Biology; 1999; No. 77; pp. 469-475.
Marguiles, Barry J. et al.: “Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles”;Virology; 1996; vol. 225 No. 0579; pp. 111-125; Academinc Press, Inc.
Padia, Janak K. et al: “Novel nonpeptide CCK-B antagonists: Design and development of quinozalone derivatives as potent, selective, and orally active CCK-B antagonists”;J. Med. Chem; 1998; vol. 41; pp. 1042-1049; American Chemical Society.
Padia, Janak K. et al.: “Design and synthesis of novel nonpeptide CCK-B receptor antagonists”;Bioorganic&Medical Chemistry Letters; 1997; vol. 7, No. 7; pp. 805-810; Elsevier Science Ltd.
Penfold, Mark E. T. et al.: “Cytomegalovirus encodes a potent α chemokine”;Proc. Natl. Acad. Sci. USA; Aug. 1999; vol. 96; pp. 9839-9844.
Rollins, Barrett J.: “
Dairaghi Daniel J.
McMaster Brian E.
Penfold Mark
Schall Thomas J.
Wright J. J.
ChemoCentryx, Inc.
Wang Shengjun
LandOfFree
Bicyclic compounds as inhibitors of chemokine binding to US28 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic compounds as inhibitors of chemokine binding to US28, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic compounds as inhibitors of chemokine binding to US28 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3593778